Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Some analysts think it is likely to be an also-ran in the market, with EvaluatePharma predicting around $110 million in sales in 2024, although others are more…
"Technologies such as Crispr are highly valued," says a study by the British analysis company EvaluatePharma, "but they also represent a high risk. Any serious setback…
The sell-side expects tucatinib to post 2024 sales of $268 million, according to EvaluatePharma consensus.
According to estimates by market research firm Evaluate Pharma, the annual increase in prescription drug sales between 2019 and 2024 will reach almost 7% worldwide.
EvaluatePharma consensus predicts 2024 palovarotene sales of $357m; there are currently no forecasts for BLU-782, presumably because of its early stage.
According to an estimate by data service provider EvaluatePharma, about $ 182 billion will be spent on research and development this year, much of it to fight more than…
The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…
This latest approval will allow Keytruda to continue on its upwards trajectory – Evaluate Pharma has forecasted that it will be the top-selling drug worldwide in 2024 at…
Analysts think that Beovu has the potential to grow quickly to blockbuster sales levels, with...EvaluatePharma pegging it at a more modest $1.3bn in 2024.
Doptelet could be worth more to the Swedish group, according to EvaluatePharma's NPV analyser.